GMED
Globus Medical, Inc. NYSE$90.03
Pre-mkt
$90.75
+0.80%
Mkt Cap $12.2B
52w Low $51.79
77.1% of range
52w High $101.40
50d MA $90.17
200d MA $77.22
P/E (TTM)
22.9x
EV/EBITDA
15.6x
P/B
2.7x
Debt/Equity
0.0x
ROE
11.8%
P/FCF
20.0x
RSI (14)
—
ATR (14)
—
Beta
1.09
50d MA
$90.17
200d MA
$77.22
Avg Volume
1.1M
About
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | 1.06 | 1.28 | +20.8% | 91.88 | +0.5% | +4.7% | +5.3% | +3.9% | +2.1% | -0.2% | — |
| Nov 6, 2025 | AMC | 0.78 | 1.18 | +51.1% | 61.71 | +29.6% | +35.9% | +39.9% | +37.6% | +37.3% | +36.1% | — |
| Aug 7, 2025 | AMC | 0.76 | 0.86 | +13.2% | 54.07 | +3.6% | +8.5% | +9.9% | +14.4% | +16.1% | +11.0% | — |
| May 8, 2025 | AMC | 0.74 | 0.68 | -8.6% | 72.46 | -15.9% | -23.0% | -18.6% | -19.6% | -19.7% | -20.2% | — |
| Feb 20, 2025 | AMC | 0.74 | 0.84 | +13.5% | 84.12 | -1.5% | -4.6% | -4.9% | -5.4% | -4.9% | -6.5% | — |
| Nov 5, 2024 | AMC | 0.65 | 0.83 | +28.3% | 75.58 | +7.8% | +9.4% | +8.5% | +7.0% | +8.5% | +10.4% | — |
| Aug 6, 2024 | AMC | 0.68 | 0.75 | +10.3% | 69.05 | +7.5% | +2.1% | +7.1% | +6.0% | +5.8% | -2.5% | — |
| May 7, 2024 | AMC | 0.57 | 0.72 | +27.0% | 51.36 | +13.3% | +20.2% | +25.3% | +26.0% | +24.1% | +22.4% | — |
| Feb 20, 2024 | AMC | 0.59 | 0.60 | +1.7% | 54.16 | -1.1% | +1.6% | +2.0% | +3.9% | +3.2% | +4.2% | — |
| Nov 7, 2023 | AMC | 0.54 | 0.57 | +5.6% | 46.19 | -1.8% | -0.7% | -5.0% | -4.4% | -5.2% | -0.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $96.22 | $96.64 | +0.4% | +0.5% | -0.8% | -2.5% | -4.7% | -6.0% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $91.88 | $92.33 | +0.5% | +4.7% | +5.3% | +3.9% | +2.1% | -0.2% |
| Feb 25 | Barclays | Maintains | Overweight → Overweight | — | $91.88 | $92.33 | +0.5% | +4.7% | +5.3% | +3.9% | +2.1% | -0.2% |
| Jan 30 | Needham | Upgrade | Hold → Buy | — | $90.22 | $91.75 | +1.7% | +0.5% | -0.6% | -3.1% | -3.5% | -3.0% |
| Jan 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $94.62 | $95.77 | +1.2% | -0.2% | -3.1% | -4.7% | -2.3% | -0.8% |
| Jan 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $90.54 | $100.10 | +10.6% | +4.5% | +4.3% | +1.3% | -0.4% | +2.1% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $85.79 | $85.48 | -0.4% | -0.9% | +1.3% | +1.5% | +4.2% | +3.5% |
| Dec 17 | RBC Capital | Maintains | Outperform → Outperform | — | $85.79 | $85.48 | -0.4% | -0.9% | +1.3% | +1.5% | +4.2% | +3.5% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $89.79 | $89.70 | -0.1% | -0.8% | -2.3% | -1.2% | +1.5% | -0.9% |
| Nov 18 | Truist | Maintains | Buy → Buy | — | $83.64 | $83.57 | -0.1% | -0.3% | +0.2% | -1.6% | +2.8% | +5.2% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
GMED's executive change, with Kelly G. taking a signing authority role as of March 2026, suggests potential leadership reorganization that could impact strategic direction and operational continuity for investors monitoring management stability.
Mar 23
8-K
GLOBUS MEDICAL INC -- 8-K Filing
Globus Medical reported full-year 2025 results showing musculoskeletal technology company performance, though specific financial metrics require review of detailed earnings data.
Feb 24
Data updated apr 25, 2026 11:46am
· Source: massive.com